Summary
Liquidia Technologies has filed proposed terms for its upcoming U.S. IPO.
The firm is developing reformulations for existing, approved drugs.
LQDA enjoys strong investor support for the IPO and for its lower-risk regulatory approach.
This idea was discussed in more depth with members of my private investing community, IPO Edge.
Quick Take
Liquidia Technologies (LQDA) intends to raise $50 million from the sale of its common stock in a U.S. IPO, according to an amended S-1/A registration statement.
The company is advancing a pipeline of already-approved treatments using its proprietary dry inhaled technology.
LQDA is pursuing a lower regulatory risk approach, has strong existing investor support for the IPO and a significant collaboration with GlaxoSmithKline (GSK).
